Pragmatic Trial to Study the Cost-Effectiveness of MyPhenome-RX Test to Guide Anti-Obesity Pharmacotherapy | NCT07728812

NCT07728812

Overview

NCT ID: NCT07728812
Lead Sponsor: Phenomix SciencesINDUSTRY
Official Title: Pragmatic Trial to Study the Cost-Effectiveness of MyPhenome-RX Test to Guide Anti-Obesity Pharmacotherapy (PhenoRX Pragmatic Trial)
Brief Summary: A pragmatic, randomized, parallel-arm, controlled study of weight loss outcomes using AOMs guided by MyPhenome test.
Conditions: Obesity & Overweight
Interventions: Genetic Test
Anti-Obesity Medication (AOM) treatment

Status and Timeline

Status: Not yet recruiting
Last Update Posted: Jul 27, 2026Actual
Start Date: Sep 1, 2026Estimated
Primary Completion Date: Jul 1, 2028Estimated
Completion Date

Participation Criteria

Ages Eligible for Study: Adult (18-64)Older Adult (65+)
Sexes Eligible for Study: All
Accepts Healthy Volunteers?: No
Eligibility Criteria: Inclusion Criteria:

Adults - age 18 or older

obesity (BMI ≥ 30 kg/m2) without obesity related diseases (ORDs). Or obesity (BMI ≥ 27 kg/m2) with obesity related diseases (ORDs).

Mayo Clinic employee or dependent

Referred to Community Internal Medicine Weight Management Program

Exclusion Criteria:

Pregnancy or currently breast feeding.

No contraindications to the weight loss medications: Phentermine-Topiramate Extended Release (Qsymia®); Oral naltrexone extended-release/bupropion extended-release (NBSR; Contrave®, Mysimba™); Liraglutide (Saxenda®), Semaglutide (Wegovy®), and Tirzepatide (Zepbound®).

Study Plan

Study Type: Interventional
Phase: Not Applicable
Enrollment: 424Estimated
Primary Purpose: Treatment
Allocation: Randomized
Interventional Model: Parallel Assignment
Masking: Double

Contacts and Locations

Central Contacts: No data available
Locations: No data available

Similar Studies

Participant Group/Arms

Standard of Care Medication SelectionActive Comparator

Patients randomized to this group will be prescribed the medications based on Mayo Clinic Community Internal Medicine Weight Management Program guidelines.

Drug: Anti-Obesity Medication (AOM) treatment

MyPhenome TestExperimental

Patients randomized to this group will take the MyPhenome Test. Results will be returned and the High CTSGRS (Hungry Brain) phenotype will be assigned to Phentermine-topiramate ER, low CTSGRS (Hungry Gut) phenotype will be assigned to GLP-1 receptor agonists (semaglutide or tirzepatide) and the emotional eating phenotype will be assigned to naltrexone-bupropion SR.

Genetic: Genetic Test